2012
YM155 sensitivity in pediatric acute lymphoblastic leukemia.
Chang B, Jemal A, Tyner J, Thayer M, Muschen M, Druker B. YM155 sensitivity in pediatric acute lymphoblastic leukemia. Journal Of Clinical Oncology 2012, 30: 9555-9555. DOI: 10.1200/jco.2012.30.15_suppl.9555.Peer-Reviewed Original ResearchPediatric acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaPhase I/II studyNCI standard riskStandard intensive chemotherapyProtein expressionSubset of patientsAdditional therapeutic agentsB-cell malignanciesYM155 treatmentIntensive chemotherapyII studyPhospho-flow cytometryPrimary patientsCombination therapyAnnexin V bindingTarget effectsNovel agentsPossible efficacyHigh riskStandard riskIsobologram analysisMultiple protein expressionMalignant cells
2001
Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells.
Re D, Müschen M, Ahmadi T, Wickenhauser C, Staratschek-Jox A, Holtick U, Diehl V, Wolf J. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Research 2001, 61: 2080-4. PMID: 11280769.Peer-Reviewed Original ResearchConceptsImmunoglobulin gene expressionH-RS cellsGene expressionOct-2 transcriptsOct-2 proteinTranscription factor Oct-2Primary H-RS cellsCell linesTranscription machineryBob-1Gene deregulationOctamer siteHodgkin's disease-derived cell linesImmunoglobulin genesNovel mechanismGerminal center B cellsCrippling mutationsClassical Hodgkin's diseaseProtein expressionB cellsTranscriptsExpressionProteinReed-Sternberg cellsCells